Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, United States.
National Heart, Lung, and Blood, Institute, National Institutes of Health, Bethesda, MD, United States.
Front Immunol. 2024 Sep 11;15:1448780. doi: 10.3389/fimmu.2024.1448780. eCollection 2024.
Limited data are available describing the effects of SARS-CoV-2 breakthrough infections on the plasma proteome.
PCR-positive SARS-CoV-2 patients, enrolled in a natural history study, underwent analysis of the plasma proteome. A prospective cohort of 66 unvaccinated and 24 vaccinated persons with different degrees of infection severity were evaluated acutely (within 40 days of symptom onset), and at three and ten months. Comparisons based on vaccination status alone and unsupervised hierarchical clustering were performed. A second cohort of vaccinated Omicron patients were evaluated acutely and at ten months.
Acutely, unvaccinated patients manifested overexpression of proteins involved in immune and inflammatory responses, while vaccinated patients exhibited adaptive immune responses without significant inflammation. At three and ten months, only unvaccinated patients had diminished but sustained inflammatory (C3b, CCL15, IL17RE) and immune responses (DEFA5,TREM1). Both groups had underexpression of pathways essential for cellular function, signaling, and angiogenesis (AKT1, MAPK14, HSPB1) across phases. Unsupervised clustering, based on protein expression, identified four groups of patients with variable vaccination rates demonstrating that additional clinical factors influence the plasma proteome. The proteome of vaccinated Omicron patients did not differ from vaccinated pre-Omicron patients.
Vaccination attenuates the inflammatory response to SARS-CoV-2 infection across phases. However, at ten months after symptom onset, changes in the plasma proteome persist in both vaccinated and unvaccinated individuals, which may be relevant to post-acute sequelae of SARS-CoV-2 and other viral infections associated with post-acute infection syndromes.
目前关于 SARS-CoV-2 突破感染对血浆蛋白质组影响的数据有限。
PCR 阳性的 SARS-CoV-2 患者入组自然史研究,分析血浆蛋白质组。评估了 66 例未接种疫苗和 24 例接种疫苗的急性(症状出现后 40 天内)和 3 个月及 10 个月的不同严重程度感染患者,单独基于接种状态和无监督层次聚类进行比较。评估了第二组接种 Omicron 的患者的急性和 10 个月情况。
急性感染时,未接种疫苗的患者表现出免疫和炎症反应相关蛋白的过度表达,而接种疫苗的患者则表现出适应性免疫反应而无明显炎症。3 个月和 10 个月时,只有未接种疫苗的患者炎症(C3b、CCL15、IL17RE)和免疫反应(DEFA5、TREM1)持续减弱。两个组的细胞功能、信号转导和血管生成必需途径(AKT1、MAPK14、HSPB1)的蛋白表达均下调。基于蛋白表达的无监督聚类,确定了 4 组具有不同接种率的患者,表明其他临床因素会影响血浆蛋白质组。接种 Omicron 的患者的蛋白质组与接种前 Omicron 的患者无差异。
接种疫苗可减轻 SARS-CoV-2 感染各阶段的炎症反应。然而,在症状出现后 10 个月,接种和未接种患者的血浆蛋白质组仍持续变化,这可能与 SARS-CoV-2 及其他与急性后感染综合征相关的病毒感染的急性后后遗症有关。